Butyrylcholinesterase as a biochemical marker

Bratislava Medical Journal

Volumn 114, Issue 12, 2013, Pages 726-734

  Pohanka, M ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acetylcholinesterase; AChE; Alzheimer's disease; BChE; Butyrylcholinesterase; Carbamate; Dibucaine number; K variant; Liver function test; Organophosphate; Poisoning

Indexed keywords

BIOLOGICAL MARKER; CHOLINESTERASE;

ANIMAL; BLOOD; BUTYRYLCHOLINESTERASE; ACETYLCHOLINESTERASE; LIVER FUNCTION TEST; ORGANOPHOSPHATE; CARBAMATE; POISONING; DIBUCAINE NUMBER; ALZHEIMER'S DISEASE; BCHE; ACHE; K VARIANT.; DISEASE COURSE; ENZYMOLOGY; HUMAN; LIVER DISEASE; REVIEW;

BUTYRYLCHOLINESTERASE; ACETYLCHOLINESTERASE; LIVER FUNCTION TEST; ORGANOPHOSPHATE; CARBAMATE; POISONING; DIBUCAINE NUMBER; ALZHEIMER'S DISEASE; BCHE; ACHE; K VARIANT.;

ANIMALS; BIOLOGICAL MARKERS; BUTYRYLCHOLINESTERASE; DISEASE PROGRESSION; HUMANS; LIVER DISEASES;

EID: 84890862628     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2013_153     Document Type: Review

References (86)

1. Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Olomouc 2011; 155: 219-230.
2. Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2012; 37: 16-42.
3. Pohanka M , Snopkova S, Havlickova K, Bostik P, Sinkorova Z, Fusek J, Kuca K, Pikula J. Macrophage-assisted inflammation and pharmacological regulation of the cholinergic anti-inflammatory pathway. Curr Med Chem 2011; 18: 539-551.
4. Chen A, Du D, Lin Y. Highly sensitive and selective immuno-capture/ electrochemical assay of acetylcholinesterase activity in red blood cells: a biomarker of exposure to organophosphorus pesticides and nerve agents. Environ Sci Technol 2012; In press.
5. Nigg HN, Knaak JB. Blood cholinesterases as human biomarkers of organophoshorus pesticide exposure. Rev Environ Contam Toxicol 2000; 163: 29-111.
6. Rojas-Garcia AE, Medina-Diaz IM, Robledo-Marenco Mde L, Barron-Vivanco BS, Giron-Perez MI, Velazquez-Fernandez JB, Gonzalez-Arias CA, Albores-Medina A, Quintanilla-Vega B, Ostrosky-Wegman P, Rojas-Garcia MC, Perez-Herrera NE, Lopez-Flores JF. Hematological, biochemical effects, and self-reported symptoms in pesticide retailers. J Occup Environ Med 2011; 53: 517-521.
7. Boopathy R, Rajesh RV, Darvesh S, Layer PG. Human serum cholinesterase from liver pathological samples exhibit highly elevated aryl acylamidase activity. Clin Chim Acta 2007; 380: 151-156.
8. Cygler M, Schrag JD, Sussman JL, Harel M, Silman I, Gentry MK, Doctor BP. Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and realted enzymes. Prot Sci 1993; 2: 366-382.
9. Lockridge O , Bartels CF, Vaughan TA, Wong CK, Norton SE, Johnson LL. Complete amino acid sequence of human serum cholinesterase. J Biol Chem 1987; 262: 549-557.
10. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003; 278: 41141-41147.
11. Masson P, Xie W, Fromet MT, Levitsky V, Fortier PL, Albaret C, Lockridge O. Interaction between the peripheral site residues of human butyrylcholinesterase, D70 and Y332, in binding and hydrolysis of substrates. Biochim Biophys Acta 1999; 1433: 281-293.
12. Saxena A, Redman AM, Jiang X, Lockridge O, Doctor BP. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 1997; 36: 14642-14651.
13. Kaplan D, Ordentlich A, Barak D, Ariel N, Kronman C, Velan B, Shafferman A. Deos "butyrylization" of acetylcholinesterase though substitution of the six divergent aromatic amino acids in the active center gorge generate an enzyme mimic of butyrylcholinesterase. Biochemistry 2001; 40: 7433-7445.
14. Saxena A, Redman AM Jiang X, Lockridge O, Doctor BP. Differences in active-site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Chem Biol Interact 1999; 119: 61-69.
15. Suarez D , Diaz N, Fontecilla-Camps J, Field MJ. A computatonal study of the deacylation mechanism of human butyrylcholinesterase. Biochemistry 2006; 45: 7529-7543.
16. Sokolova NV, Nenajdenko VG, Sokolov VB, Serebryakova OG, Makhaeva GF. Synthesis and testing of trifluoromethyl-containing phosphonate-peptide conjugates as inhibitors of serine hydrolases. Bioorg Med Chem Lett 2011; 21: 7216-7218.
17. Li B, Duysen EG, Carlson M, Lockridge O. The butyrylcholinesterase knockout mouse as a model for human butyrylcholinesterase deficiency. J Pharmacol Exp Ther 2008; 324: 1146-1154.
18. Hidaka K, Iuchi I, Yamasaki T, Ueda N, Hukano K. Nonsence mutation in exon 2 of the butyrylcholinesterase gene: a case of familial cholinesterasemia. Clin Chim Acta 1997; 261: 27-34.
19. Sakamoto N, Maeda T, Hidaka K, Teranishi T, Toyoda M, Onishi Y, Kuroda S, Sakaguchi K, Fujisawa T, Maeda M, Watanabe Y, Iuchi I. Identification of missense mutation (G365R) of the butyrylcholinesterase (BChE) gene in a Japanese patient with familial cholinesterasemia. Kobe J Med Sci 2001; 47: 153-160.
20. Hidaka K, Iuchi I, Tomita M, Watanabe Y, Minatogawa Y, Iwasaki K, Gotoh K, Shimizu C. Genetic analysis of a Japanese patient with butyrylcholinesterase deficiency. Ann Hum Genet 1997; 61: 491-496.
21. Kaufman SE , Donnell RW, Aiken DC, Magee C. Prolonged neuromuscular paralysis following rapid-sequence intubation with succinylcholine. Ann Pharmacother 2011; 45: e21.
22. Yuan J , Yin J, Wang E. Characterization of procaine metabolism as probe for the butyrylcholinesterase enzyme investigation by simultaneous determination of procaine and its metabolite using capillary electrophoresis with electrochemiluminescence detection. J Chromatogr A 2007; 1154: 368-372.
23. Moriarty L M, Lally MN, Carolan CG, Jones M, Clancy JM, Gilmer JF. Discovery of a "true" aspirin prodrug. J Med Chem 2008; 51: 7991-7999.
24. Galenko-Yaro shevskii AP, Derlugov LP, Ponomarev VV, Dukhanin AS. Pharmacokinetics and pharmacodynamics of a new local anesthetic agent. Bull Exp Biol Med 2003; 136: 170-173.
25. Masson P, Froment MT, Fortier PL, Visicchio JE, Bartels CF, Lockridge O. Butyrylcholinesterase-catalysed hydrolysis of aspirin, a negatively charged ester, and aspirin-related neutral esters. Biochim Biophys Acta 1998; 1387: 41-52.
26. Duysen E G, Lockridge O. Prolonged toxic effects after cocaine challenge in butyrylcholinesterase/plasma carboxylesterase double knockout mice: a model for butyrylcholinesterase-deficient humans. Drug Metab Dispos 2011; 39: 1321-1323.
27. Larsen NA, Turner JA, Stevens J, Rosser SJ, Basran A, Lerner RA, Bruce NC, Wilson IA. Crystal structure of a bacterial cocaine esterase. Nat Struct Biol 2001; 9: 17-21.
28. Duysen E G, Li B, Carlson M, Li YF, Wieseler S, Hinrichs SH, Lockridge O. Increased hepatotoxicity and cardiac fibrosis in cocaine-treated butyrylcholinesterase knockout mice. Basic Clin Pharmacol Toxicol 2008; 103: 514-521.
29. Hartmann J , Kiewert C, Duysen EG, Lockridge O, Greig NH, Klein J. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem 2007; 100: 1421-1429.
30. Duysen EG, Li B, Darvesh S, Lockridge O. Sensitivity of butyrylcholinesterase knockout mice to (-)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Toxicology 2007; 233: 60-69.
31. Manoharan I, Boopathy R, Darvesh S, Lockridge O. A medical health report on individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta 2007; 378: 128-135.
32. Darvesh S, Hopkins DA. Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus. Darvesh S, Hoplins DA 2003; 463: 25-43.
33. Masson P , Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: Catalytic complexities and hysteretic behavior. Arch Biochem Biophys 2010; 494: 107-120.
34. Hada T, Yamawaki M, Moriwaki Y, Tamura S, Yamamoto T, Amuro Y, Nabeshima K, Higashino K. Hypercholinesterasemia with isoenzymic alteration in a family. Clin Chem 1985; 31: 1997-2000.
35. Nagai K, Sakata S, Kametani M, Gomi K, Tokimitsu N, Mura K. Familiar hypercholinesterasemia. A case report. Jpn J Med 1986; 25: 313-316.
36. Ohkawa J, Oimomi M, Baba S. Familiar hypercholinesterasemia. Kobe J Med Sci 1989; 35: 39-45.
37. Tajiri J , Nishizono Y, Fujiyama S, Sagara K, Sato T, Shibata H. Hypercholinesterasemia in patients with hepatocellular carcinoma: a new paraneoplastic syndrome. Gastroenterol Jpn 1983; 18: 137-141.
38. Garcia DF, Oliveira TG, Molfetta GA, Garcia LV, Ferreira CA, Marques AA, Silva WA. Biochemical and genetic analysis of butyrylcholinesterase (BChE) in a family, due to prolonged neuromuscular blockade after the use of succinylcholine. Genet Mol Biol 2011; 34: 40-44.
39. Liu W, Hada T, Fukui K, Imanishi H, Matsuoka N, Iwasaki A, Higashino K. Familial hypocholinesterasemia found in a family and a new confirmed mutation. Intern Med 1997; 36: 9-13.
40. Kawano Y, Mizuta K, Hisikawa S, Saito T, Egami S, Takatsuka Y, Sanada Y, Fujiwara T, Yasuda Y, Ohmori M, Sakamoto K, Liu W, Nishiguchi S, Hada T, Kawarasaki H. Successful pediatric living donor liver transplantation from carrier to carrier of hereditary butyrylcholinestease variant. Pediatr Transplant 2007; 11: 694-697.
41. Prellwitz W, Kapp S, Muller D. Comparative methods for the determination of the activity of serumcholinesterases (acylcholin-acyl-hydrolase E.C. 3.1.1.8) and their diagnostical value. J Clin Chem Clin Biochem 1976; 14: 93-97.
42. Jezyna C . Correlation of changes in hypocholinesterasemia and hypoalbuminemia in virus hepatitis. Przegl Lek 1969; 25: 515-519.
43. Kemkes-Matthes B, Preissner KT, Langenscheidt F, Matthes KJ, Muller-Berghaus G. S protein/vitronectin in chronic liver diseases: correlations with serum cholinesterase, coagulation factor X and complement component C3. Eur J Haematol 1987; 39: 161-165.
44. Duran-Ferreras E, Diaz-Narvaez F, Raffo-Marquez M. Chronic hepatic encephalopathy in a patient with primary biliary cirrhosis. Gastroenterol Hepatol 2011; 34: 401-405.
45. Pohanka M. Alzheimer's disease and related neurodegenerative disorders: implication and counteracting of melatonin. J Appl Biomed 2011; 9: 185-196.
46. Abdullat I M, Battah AH, Hadidi KA. The use of serial measurement of plasma cholinesterase in the management of acute poisoning with organophosphates and carbamates. Forensic Sci Int 2006; 162: 126-130.
47. Aroud M, Neffeti F, Douki W, Najjar MF, Kenani A. Paraoxonase 1 correlates with butyrylcholinesterase and gamma glutamyl transferase in workers chronically exposed to pesticides. J Occup Health 2010; 52: 383-388.
48. Eddleston M, Eyer P, Worek F, Sheriff MHR, Buckley NA. Predicting outcome using butyrylcholinesterase activity in organophoshorus pesticide self-poisoning. QJM 2008; 101: 467-474.
49. Vaisi-Raygani A, Rahimi Z, Entezami H, Kharrazi H, Bahrhemand F, Tavilani H, Rezaei M, Kiani A, Nomanpour B, Pourmotabbed T. Butyrylcholiensterase K variants increase the risk of coronary artery disease in the population of western Iran. Scand J Clin Lab Invest 2008; 68: 123-129.
50. Vaisi-Raygani A, Rahimi Z, Tavilani H, Pourmotabbed T. Butyrylcholinesterase K variant and the APOE-epsilon 4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients. Mol Biol Rep 2010; 37: 2083-2091.
51. Pestel G, Sprenger H, Rothhammer A. Frequency distribution of dibucaine numbers in 24,830 patients. Anaesthesis 2003; 52: 495-499.
52. Hosseini J , Firuzian F, Feely J. Ethnic differences in the frequency distribution of serum cholinesterase activity. Ir J Med Sci 1997; 166: 10-12.
53. Akizuki S, Sudo K, Abe M, Abe I, Nakajima T, Ohnishi A, Maekawa M. Dibucaine number (DN) and fluoride number (FN) of L330 I mutant recombinant cholinesterase by use of various substrates. Rinsho Byori 1999; 47: 479-480.
54. Parnas ML, Procter M, Schwarz MA, Mao R, Grenache DG. Concordance of butyrylcholinesterase phenotype with genotype implications for biochemical reporting. Am J Clin Pathol 2011; 135: 271-276.
55. Lee G, Robinson JC. Agar diffusion test for serum cholinesterase typing and incluence of temperature on dibucaine and fluoride numbers. J Med Genet 1967; 4: 19-25.
56. Kallow W , Genest K. A method for the detection of human serum cholinesterase: determnation of dibucaine numbers. Can J Biochem 1957; 35: 339-346.
57. Patterson CE, Todd SA, Passmore AP. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. Pharmacogen J 2011; 11: 444-450.
58. Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, Ahmed H, Almkvist O, Langstrom B, Nordberg A. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging 2011; 32: 2320.e15.
59. Sridhar GR, Rao AA, Srinivas K, Nirmala G, Lakshmi G, Suryanarayna D, Rao PN, Kladhar DG, Kumar SV, Devi TL, Nitesh T, Hanuman T. Butyrylcholinesterase in metabolic syndrome. Med Hyp 2010; 75: 648-651.
60. Verghese P B, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011; 10: 241-252.
61. Darreh-Shory T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, Andreasen N, Nordberg A. The apolipoprotein E epsilon 4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. Neurobiol Aging 2011; 32: 1236-1248.
62. Holmes C, Ballard C, Lehmann D, Smith AD, Beaumont H, Day IN, Khan MN, Lovestone S, McCulley M, Morris CM, Munoz DG, O'Brien K, Russ C, Del Ser T, Warden D. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005; 76: 640-643.
63. Bizzarro A , Guglielmi V, Lomastro R, Valenza A, Lauria A, Marra C, Silver MC, Tizlano FD, Brahe C, Masullo C. BuChE K variant is decreased in Alzheimer's diasease not in fronto-temporal dementia. J Neur Transm 2010; 117: 377-383.
64. Pohanka M, Musilek K, Kuca K. Progress of biosensors based on cholinesterase inhibition. Curr Med Chem 2009; 16: 1790-1798.
65. Masson P, Froment MT, Gillon E, Nachon F, Darvesh S, Schopfer LM. Kinetic analysis of butyrylcholinesterase-catalyzed hydrolysis of acetanilides. Biochim Biophys Acta 2007; 1774: 1139-1147.
66. Montenegro M F, Moral-Naranjo MT, de la Cadena MP, Campoy FJ, Monoz-Delgado E, Vidal CJ. The level of aryl acylamidase activity displayed by human butyrylcholinesterase depends on its molecular distribution. Chem Biol Interact 2008; 175: 336-339.
67. Montenegro MF, Maria TM, de la Cadena MP, Campoy FJ, Munoz-Delgado E, Vidal CJ. Human butyrylcholinesterase components differ in aryl acylamidase activity. Biol Chem 2008; 389: 425-432.
68. Reubsaet J L, Ringvold A. Identification of unknown quaternary ammonium compounds in corneal epithelium and aqueous humor. J Chromatogr Sci 2005; 43: 401-405.
69. deVos T, Dick TA. Characterization of cholinesterases from the parasitic nematode Trichinella spiralis. Comp Biochem Physiol C 1992; 103: 129-134.
70. Tormos JR, Wiley KL, Seravalli J, Nachon F, Masson P, Nicolet Y, Quinn DM. The reactant state for substrate-activated turnover of acetylthiocholine by butyrylcholinesterase is a tetrahedral intermediate. J Am Chem Soc 2005; 127: 14538-14539.
71. Altamirano CV, Bartels CF, Lockridge O. The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme. J Neurochem 2000; 74: 869-877.
72. Masson P, Goldstein BN, Debouzy JC, Froment MT, Lockridge O, Schopfer LM. Damped oscillatory hysteretic behaviour of butyrylcholinesterase with benzoylcholine as substrate. Eur J Biochem 2004; 271: 220-234.
73. Sun H, Yazal J, Lockridge O, Schopfer LM, Brimijoin S, Pang YP. Predicted Michaelis-Menten complexes of cocaine-butyrylhcolinesterase. Engineering effective butyrylholinesterase mutants for cocaine detoxication. J Biol Chem 2001; 276; 9330-9336.
74. Weingand-Ziade A, Ribes F, Renault F, Masson P. Pressure-and heat induced inactivation of butyrylcholinesterase: evidence for multiple intermediates and the remnant inactivation process. Biochem J 2001; 356: 487-493.
75. Reiner E, Simeon-Rudolf V, Skrinjaric-Spoljar M. Catalytic properties and distribution profiles of paraoxonase and cholinesterase phenotypes in human sera. Toxicol Lett 1995; 82: 447-452.
76. Masson P, Xie W, Froment MT, Lockridge O. Effects of mutations of active site residues and amino acids interacting with the W loop on substrate activation of butyrylcholinesterase. Biochim Biophys Acta 2001; 1544: 166-176.
77. Ellman GL, Courtney DK, Andreas V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
78. Pohanka M, Pikula J, Kuca K, Kassa J. Biochemical insight into soman intoxication and treatment with atropine, HI-6, trimedoxime, and K203 in a rat model. Bratislava Med J 2011; 112: 539-544.
79. Pezzementi L, Nachon F, Chatonnet A. Evolution of acetylcholinesterase and butyrylcholinesterase in the vertebrates: an atypical butyrylcholinesterase from the Medaka Oryzias latipes. PLoS One 2011; 6: e17396.
80. Wu ZL, Podust MLM, Guengerich FP. Expansion of substrate specificity of cytochrome P450 2A6 by random and site-directed mutagenesis. J Biol Chem 2005; 280: 41090-41100.
81. de Melo JS, Rondao R, Burrows HD, Melo MJ, Navaratnam S, Edge R, Voss G. Photophysics of an indigo derivative (keto and leuco structures) with singular properties. J Phys Chem A 2006; 110: 13653-13661.
82. Pohanka M, Hrabinova M, Kuca K, Simonato JP. Assessment of acetylcholinesterase activity using indoxylacetate and comparison with the standard Ellman's method. Int J Mol Sci 2011; 12: 2631-2640.
83. No HY, Kim YA, Lee YT, Lee HS. Cholinesterase-based dipstick assay for the detection of organophosphate and carbamate pesticides. Anal Chim Acta 2007; 594: 37-43.
84. Pohanka M. Acetylcholinesterase based dipsticks with indoxylacetate as a substrate for assay of organophosphates and carbamates. Anal Lett, In press, DOI: 10.1080/00032719.2011.644743.
85. Miao Y, He N, Zhu JJ. History and new developments of assays for cholinesterase activity and inhibition. Chem Rev 2010; 110: 5216-5234.
86. Tingfa D, Shiquang Z, Mousheng T. A new micro-detection tube for cholinesterase inhibitors in water. Environ Pollut 1989; 57: 217-222.